Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CVRx, Inc.CVRX · Entity 6920 | Director | June 01, 2026 | June 03, 2026 |
| Ominto, Inc.OMNT · Entity 164576 | Director | December 08, 2016 | January 12, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CVRx, Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,720 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 8,720 · Balance 8,720 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.43 · Expires 2036-06-01 | Direct | 11,182 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 11,182 · Balance 11,182 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.
Ominto, Inc.
Report date December 08, 2016 · Filed January 12, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2026-12-07 | Direct | 90,000 |
Reported balance
After 2016-12-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2016-12-08 · Grant · Acquired 70,000 · Balance 90,000 F1: Reflects an increase to exercise price as determined by the Issuer's Board of Directors. F2: Reflects the issuance of 70,000 options, which was originally reported on December 13, 2016 as 250,000 options, 180,000 of which were subsequently revoked prior to vesting. F3: Options vest over 30 month period. F4: This amendment is being filed to correct the expiration date of the option from the Form 4 dated May 18, 2017. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2026-12-07 | Direct | 120,000 |
Reported balance
After 2016-12-08 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2016-12-08 · Grant · Acquired 30,000 · Balance 120,000 F1: Reflects an increase to exercise price as determined by the Issuer's Board of Directors. F5: Options vest as follows: 5,000 options vested on the grant date, the remaining vest at a rate of 1/36 per month. F4: This amendment is being filed to correct the expiration date of the option from the Form 4 dated May 18, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an increase to exercise price as determined by the Issuer's Board of Directors.
F2: Reflects the issuance of 70,000 options, which was originally reported on December 13, 2016 as 250,000 options, 180,000 of which were subsequently revoked prior to vesting.
F3: Options vest over 30 month period.
F4: This amendment is being filed to correct the expiration date of the option from the Form 4 dated May 18, 2017.
F5: Options vest as follows: 5,000 options vested on the grant date, the remaining vest at a rate of 1/36 per month.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date October 01, 2024 · Filed October 02, 2024
Section 16 reporting ended · disclosed 2024-10-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 177,533 |
Ending reported balance
After 2024-10-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-10-01 · Tax withholding · Disposed 331 · Balance 179,269 F1: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Row 2 · 2024-10-01 · Tax withholding · Disposed 616 · Balance 178,653 F2: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Row 3 · 2024-10-01 · Tax withholding · Disposed 662 · Balance 177,991 F3: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Row 4 · 2024-10-01 · Tax withholding · Disposed 458 · Balance 177,533 F4: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1,600 |
Reported balance
Holding disclosure · report date 2024-10-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,600 |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021.
F2: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022.
F3: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023.
F4: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2022 Filed Mar 17, 2022 18:02 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 300 | $76.84 | $23,052.00 |
DisclosureSEC source: 0001562180-22-002759 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,724 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F4 · price: This transaction was executed in multiple trades at prices ranging from $76.55 to $77.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 18:02 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,564 | $75.94 | $270,650.16 |
DisclosureSEC source: 0001562180-22-002759 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,024 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F3 · price: This transaction was executed in multiple trades at prices ranging from $75.49 to $76.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 18:02 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,636 | $75.04 | $272,845.44 |
DisclosureSEC source: 0001562180-22-002759 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,588 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F2 · price: This transaction was executed in multiple trades at prices ranging from $74.46 to $75.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 18:02 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 7,500 | $0.46 | $3,427.50 |
DisclosureSEC source: 0001562180-22-002759 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 19:17 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 19,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001710 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,724 F1 · shares: 2022 Annual Restricted Stock Units grant ("RSUs"). Vesting Commencement Date begins January 1, 2022, 1/16th of the RSUs shall vest on each quarterly anniversary of the vesting Commencement Date. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 18:41 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 7,500 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-22-001597 · primarydocument.xml · derivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,977 Underlying: Common Stock · 7,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F4 · derivative.exercise_date: Options vested with respected with 25% of the underlying shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment there after. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 18:41 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,196 | $79.50 | $333,582.00 |
DisclosureSEC source: 0001562180-22-001597 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,788 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F3 · price: This transaction was executed in multiple trades at prices ranging from $79.05 to $79.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 18:41 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,304 | $78.59 | $259,661.36 |
DisclosureSEC source: 0001562180-22-001597 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,984 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F2 · price: This transaction was executed in multiple trades at prices ranging from $78.04 to $78.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 18:41 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 7,500 | $0.46 | $3,427.50 |
DisclosureSEC source: 0001562180-22-001597 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 20:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 7,500 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-22-000560 · primarydocument.xml · derivative · entry 7 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,477 Underlying: Common Stock · 7,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F7 · derivative.exercise_date: Options vested with respected with 25% of the underlying shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment there after. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 20:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 600 | $78.26 | $46,954.98 |
DisclosureSEC source: 0001562180-22-000560 · primarydocument.xml · nonDerivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,788 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F5 · price: This transaction was executed in multiple trades at prices ranging from $78.03 to $78.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · balance_after: Includes 347 shares acquired under the Employee Stock Purchase Plan. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 20:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,351 | $77.35 | $181,842.80 |
DisclosureSEC source: 0001562180-22-000560 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,041 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F4 · price: This transaction was executed in multiple trades at prices ranging from $76.99 to $77.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 20:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,783 | $76.54 | $213,016.11 |
DisclosureSEC source: 0001562180-22-000560 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,392 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F3 · price: This transaction was executed in multiple trades at prices ranging from $75.96 to $76.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 20:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,766 | $75.43 | $133,201.61 |
DisclosureSEC source: 0001562180-22-000560 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,175 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F2 · price: This transaction was executed in multiple trades at prices ranging from $74.95 to $75.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 20:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 7,500 | $0.46 | $3,427.50 |
DisclosureSEC source: 0001562180-22-000560 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 17:18 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 274 | $91.27 | $25,007.98 |
DisclosureSEC source: 0001562180-22-000120 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,441 F1 · shares: Shares surrendered for tax purposes upon the vesting of 2021 annual Restricted Shares Units Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 17:49 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 910 | $80.19 | $72,971.54 |
DisclosureSEC source: 0001562180-21-007757 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,715 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F5 · price: This transaction was executed in multiple trades at prices ranging from $80.11 to $80.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 17:49 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 9,266 | $79.63 | $737,816.37 |
DisclosureSEC source: 0001562180-21-007757 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,625 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F4 · price: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 17:49 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 6,931 | $78.67 | $545,294.35 |
DisclosureSEC source: 0001562180-21-007757 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,891 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F3 · price: This transaction was executed in multiple trades at prices ranging from $78.11 to $79.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 17:49 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,893 | $77.66 | $224,661.41 |
DisclosureSEC source: 0001562180-21-007757 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,822 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021 F2 · price: This transaction was executed in multiple trades at prices ranging from $77.11 to $78.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 13, 2021 Filed Feb 11, 2022 16:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | GiftCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001409 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,288 Read SEC document |
| December 06, 2021 Filed Feb 11, 2022 16:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001409 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,788 Read SEC document |
| November 29, 2021 Filed Feb 11, 2022 16:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001409 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,788 Read SEC document |
| November 22, 2021 Filed Feb 11, 2022 16:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001409 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,788 Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 17:10 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-21-007023 · primarydocument.xml · derivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,977 Underlying: Common Stock · 5,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F4 · derivative.exercise_date: Options vested with respected with 25% of the underlying shares on April 30,2020 and vest with respect to the remaining shares in 36 equal monthly installment there after. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 17:10 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 802 | $87.22 | $69,953.57 |
DisclosureSEC source: 0001562180-21-007023 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,715 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F3 · price: This transaction was executed in multiple trades at prices ranging from $87.12 to $87.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 17:10 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,198 | $86.74 | $364,141.24 |
DisclosureSEC source: 0001562180-21-007023 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,517 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F2 · price: This transaction was executed in multiple trades at prices ranging from $86.12 to $87.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 17:10 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001562180-21-007023 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 16:49 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-21-006415 · primarydocument.xml · derivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,977 Underlying: Common Stock · 5,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Options vested with respected with 25% of the underlying shares on April 30,2020 and vest with respect to the remaining shares in 36 equal monthly installment there after. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 16:49 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 300 | $80.18 | $24,054.00 |
DisclosureSEC source: 0001562180-21-006415 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,715 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F4 · price: This transaction was executed in multiple trades at prices ranging from $80.12 to $80.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 16:49 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,401 | $79.58 | $270,635.60 |
DisclosureSEC source: 0001562180-21-006415 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,015 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F3 · price: This transaction was executed in multiple trades at prices ranging from $79.12 to $80.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 16:49 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,299 | $78.43 | $101,876.41 |
DisclosureSEC source: 0001562180-21-006415 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,416 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F2 · price: This transaction was executed in multiple trades at prices ranging from $78.11 to $79.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 16:49 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001562180-21-006415 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 17:19 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 231 | $78.70 | $18,179.70 |
DisclosureSEC source: 0001562180-21-006248 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,715 F1 · shares: Shares surrendered for tax purposes upon the vesting of 2021 annual Restricted Shares Units. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 18:58 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-21-005913 · primarydocument.xml · derivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,977 Underlying: Common Stock · 5,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Options vested with respected with 25% of the underlying shares on April 30,2020 and vest with respect to the remaining shares in 36 equal monthly installment there after. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 18:58 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,812 | $83.05 | $150,488.41 |
DisclosureSEC source: 0001562180-21-005913 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,946 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $82.74 to $83.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 18:58 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 986 | $82.16 | $81,012.42 |
DisclosureSEC source: 0001562180-21-005913 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,758 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $81.68 to $82.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 18:58 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,202 | $81.05 | $178,480.69 |
DisclosureSEC source: 0001562180-21-005913 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,744 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.56 to $81.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 18:58 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001562180-21-005913 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 18:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 20,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-21-005501 · primarydocument.xml · derivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,977 Underlying: Common Stock · 20,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vested with respected with 25% of the underlying shares on April 30,2020 and vest with respect to the remaining shares in 36 equal monthly installment there after. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 18:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 20,000 | $0.46 | $9,140.00 |
DisclosureSEC source: 0001562180-21-005501 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 13:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-21-005237 · primarydocument.xml · derivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,977 Underlying: Common Stock · 5,000 shares Expires 2029-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options vested with respected with 25% of the shares on April 30,2020 and vested with respect to the remaining shares in 36 equal monthly installment there after. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 13:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,009 | $95.84 | $96,699.03 |
DisclosureSEC source: 0001562180-21-005237 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,946 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F5 · price: This transaction was executed in multiple trades at prices ranging from $95.68 to $9612. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 240 shares acquired on July 30, 2021 under the Employee Stock Purchase Plan since the reporting person's last Form 4 filing. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 13:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,191 | $95.20 | $303,780.65 |
DisclosureSEC source: 0001562180-21-005237 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,955 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F4 · price: This transaction was executed in multiple trades at prices ranging from $94.68 to $95.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 240 shares acquired on July 30, 2021 under the Employee Stock Purchase Plan since the reporting person's last Form 4 filing. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 13:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 800 | $94.14 | $75,309.04 |
DisclosureSEC source: 0001562180-21-005237 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,146 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F2 · price: This transaction was executed in multiple trades at prices ranging from $93.68 to $94.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 240 shares acquired on July 30, 2021 under the Employee Stock Purchase Plan since the reporting person's last Form 4 filing. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 13:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001562180-21-005237 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 19:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-21-004903 · primarydocument.xml · derivative · entry 7 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,977 Underlying: Common Stock · 5,000 shares Expires 2029-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options vested with respected with 25% of the shares on April 30,2020 and vested with respect to the remaining shares in 36 equal monthly installment there after. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 19:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,762 | $93.79 | $165,251.28 |
DisclosureSEC source: 0001562180-21-004903 · primarydocument.xml · nonDerivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,706 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F5 · price: This transaction was executed in multiple trades at prices ranging from $93.48 to $94.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 19:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,502 | $92.97 | $139,638.54 |
DisclosureSEC source: 0001562180-21-004903 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,468 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F4 · price: This transaction was executed in multiple trades at prices ranging from $92.47 to $93.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 19:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,136 | $91.77 | $104,255.38 |
DisclosureSEC source: 0001562180-21-004903 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,970 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F3 · price: This transaction was executed in multiple trades at prices ranging from $91.40 to $92.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.